Avanos Medical (AVNS) Projected to Release Earnings on Tuesday

Avanos Medical (NYSE:AVNS) is expected to announce its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of $0.24 per share and revenue of $174.70 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, February 24, 2026 at 9:00 AM ET.

Avanos Medical Stock Up 1.7%

AVNS stock opened at $15.47 on Monday. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.38 and a quick ratio of 1.36. The stock has a market capitalization of $718.02 million, a P/E ratio of -1.52 and a beta of 1.09. The business has a 50-day moving average of $12.79 and a 200-day moving average of $11.99. Avanos Medical has a fifty-two week low of $9.30 and a fifty-two week high of $16.63.

Wall Street Analyst Weigh In

Several research firms have commented on AVNS. Weiss Ratings restated a “sell (d-)” rating on shares of Avanos Medical in a research note on Monday, December 22nd. Zacks Research raised shares of Avanos Medical from a “strong sell” rating to a “hold” rating in a research report on Monday, January 26th. Finally, Wall Street Zen upgraded shares of Avanos Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Reduce”.

Hedge Funds Weigh In On Avanos Medical

Institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC raised its position in Avanos Medical by 46.4% during the first quarter. AQR Capital Management LLC now owns 192,864 shares of the company’s stock worth $2,700,000 after acquiring an additional 61,095 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Avanos Medical by 4.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,955 shares of the company’s stock worth $386,000 after purchasing an additional 1,121 shares during the last quarter. Millennium Management LLC raised its holdings in shares of Avanos Medical by 508.3% in the 1st quarter. Millennium Management LLC now owns 547,740 shares of the company’s stock valued at $7,849,000 after purchasing an additional 457,703 shares during the period. Empowered Funds LLC raised its holdings in shares of Avanos Medical by 5.4% in the 1st quarter. Empowered Funds LLC now owns 162,182 shares of the company’s stock valued at $2,324,000 after purchasing an additional 8,348 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Avanos Medical by 17.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 140,810 shares of the company’s stock valued at $2,018,000 after purchasing an additional 20,541 shares during the last quarter. 95.17% of the stock is currently owned by institutional investors and hedge funds.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.